T lymphocyte inflammatory signaling

"T lymphocyte inflammatory signaling" is not a specific molecule or receptor but rather refers to a highly complex network of intracellular and intercellular signaling events that control the activation, differentiation, and effector functions of T lymphocytes during inflammation[1][2][3][4]. Key pathways include T cell receptor (TCR)-mediated activation (involving tyrosine kinases such as Fyn and Lck, and downstream factors like NF-κB, NFAT, and AP-1[1][3][5]), as well as costimulatory and inhibitory receptors (like CD28, CTLA-4, PD-1[2]). These pathways are modulated by cytokines (IL-2, IL-4, IL-6, IL-12, IFNγ, TGF-β), which drive T cell subset differentiation into Th1, Th2, Th17, Treg, and Tfh phenotypes[1][2][4]. The involved molecular families include kinases, transcription factors, cytokine receptors, and co-stimulatory/inhibitory molecules[1][2][3][4]. Dysregulation of this signaling network is implicated in inflammatory, autoimmune, and neoplastic diseases. However, this term does not refer to a discrete druggable entity, so it is not considered a direct therapeutic target or receptor but a process or pathway.